BPG is committed to discovery and dissemination of knowledge
Opinion Review
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 7, 2026; 32(33): 118672
Published online Sep 7, 2026. doi: 10.3748/wjg.118672
Stage-aware programmed death ligand 1 assessment in gastric cancer: Implications for perioperative immunotherapy
Hou-Shu Tu, Meng-Lin Chen, Jing Hong, Sai Li, Ling He
Hou-Shu Tu, Meng-Lin Chen, Sai Li, Department of Clinical Medicine, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, Jiangxi Province, China
Jing Hong, Department of Otorhinolaryngology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, Jiangxi Province, China
Ling He, Department of Gastroenterology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, Jiangxi Province, China
Author contributions: Tu HS and He L conceptualized and designed the opinion review; Tu HS was responsible for drafting the manuscript; Chen ML, Hong J, and Li S contributed to the critical revision of the manuscript. All authors reviewed and approved the final version for submission.
AI contribution statement: ChatGPT and language-editing tools were used for English language polishing, wording refinement, and improvement of readability during manuscript preparation. AI-based image-generation tools were also used to assist in preparing some schematic figures/graphical elements. The main text, including the abstract, introduction, main body sections, author perspectives, and conclusion, was not generated by AI as a substitute for authorial writing or intellectual contribution. All scientific content, literature selection, arguments, perspectives, and conclusions were developed, reviewed, revised, and approved by the human authors. AI-assisted tools were not used to generate original data, fabricate references, conduct data analysis, design the study, interpret results, or formulate conclusions. The AI-assisted schematic figures/graphical elements were generated based on concepts, structure, and scientific content specified by the authors, and are illustrative only. They do not represent original experimental data, clinical images, pathological images, or independently generated scientific conclusions. The authors reviewed and approved all AI-assisted language and graphical outputs and take full responsibility for the accuracy, integrity, originality, and final content of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Ling He, PhD, Professor, Department of Gastroenterology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, No. 445 Bayi Avenue, Nanchang 330006, Jiangxi Province, China. heling118@126.com
Received: January 8, 2026
Revised: January 21, 2026
Accepted: March 5, 2026
Published online: September 7, 2026
Processing time: 213 Days and 16.7 Hours
Core Tip

Core Tip: This opinion review emphasizes the stage- and context-dependent interpretation of programmed death ligand 1 (PD-L1) in gastric cancer. We summarize current advances in PD-L1 assessment, including combined positive score, spatial profiling, and multi-omics integration, and discuss how tumor stage, immune microenvironment, and T-cell functionality influence its prognostic and predictive value. The review provides a framework for integrating PD-L1 into perioperative immunotherapy, highlighting adaptive, biomarker-guided strategies to optimize patient selection and therapeutic outcomes. By bridging molecular insights with personalized treatment, this work offers practical guidance for both clinicians and researchers in precision gastric cancer management.

Write to the Help Desk